|
|
||||||||
CUTTING EDGE |


*
Institut National de la Santé et de la Recherche Médicale U448, Henri Mondor Hospital, Faculté de Medecine, Créteil, France;
Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115;
Institut National de la Santé et de la Recherche Médicale U395, Purpan University Hospital, Toulouse, France;
§
Coulter Technology Center, Miami, FL 33196; and
¶
Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|

-expressing lymphocytes (1), a subset of
CD8bright+ circulating T cells (2), and all intestinal
intraepithelial T lymphocytes (3). The BY55 molecule identifies all
lymphocytes with cytotoxic activity in PBLs and human umbilical cord
blood (4). We recently cloned BY55 cDNA, and the sequence predicts a
cysteine-rich, glycosylphosphatidylinositol-anchored molecule with a
single Ig-like domain. DNA database searches did not identify any
related human sequences, whereas protein searches revealed weak
homology to the first Ig-C2 domain of the killer inhibitory receptor
(KIR),3 KIR2DL4: 22%
identity and 44% similarity (3). KIRs deliver inhibitory signals to
the lytic machinery of NK cells after binding to specific MHC class I
molecules on target cells (5, 6). To date, no role for BY55 in NK and
CTL cytotoxicity has been identified (1, 4), which is in keeping with
its lack of immunoreceptor tyrosine-based inhibitory and activating
motifs (7). We speculated that if BY55 was also an MHC class I ligand,
it might lead to signaling in the MHC class I-bearing
"target" cell. The ligation of T cell MHC class I molecules
by mAbs in vitro can lead to inhibition (8, 9), proliferation (10, 11)
or anergy/apoptosis (12, 13). Here, we show that the BY55 molecule is a ligand for classical and nonclassical MHC class I. Most importantly, ligation of T cell MHC class I complexes by BY55 triggers a proliferative second signal to human T cell clones in the presence of soluble anti-CD3 mAb, whereas CD28 costimulation is ineffective.
| Materials and Methods |
|---|
|
|
|---|
The human T cell clones TC5 (CD4+CD8+CD28-) (14), NAR-1 (CD4+) and C-16 (CD8+) (15), and Cou LS (a human T cell lymphoma cell line) (14) were described previously. JAF43 is a CD4+ alloreactive T cell clone. T cells were purified by negative selection from normal PBLs using magnetic bead sorting (Miltenyi Biotec, Bergisch Gladbach, Germany). Chinese hamster ovary (CHO) cells were transfected with BY55 (CHO-BY55) (3), CD86 (CHO-CD86), or vector (CHO-mock) (16). J26 are murine L cells expressing human ß2-microglobulin (ß2m), whereas J26-B7 and J26-HLA-G also express human HLA-B7 and HLA-G, respectively (17). J26-HLA-E are J26 cells transfected with HLA-E containing cd3.14 cosmid (kindly donated by M. Ulbrecht, Institut für Anthropologie and Human Genetik, Munich, Germany).
Abs and tetramers
We purchased CD3-Tricolor (Caltag, Burlingame, CA), CD45-FITC (Immunotech, Marseille, France), and BY55-CYPE (Coulter, Miami, FL). Other mAbs were produced locally or obtained through exchanges of the Fifth International Workshop on the Differentiation Ags (18). Specifically, the IgM anti-BY55 mAb and CLI-R2, an IgG1 mAb, are directed against different epitopes on the BY55 molecule.
Recombinant human HLA-A2 tetramers were produced as described previously (19) and cross-linked with anti-HLA-A2 mAb (BB7.2).
Conjugate formation
A total of 2 x 105 CHO-BY55 and partner cells were centrifuged together and incubated at 37°C for 20 min. Subsequently, anti-BY55-CYPE and an FITC-conjugated mAb (specific for the partner cell) were added for 15 min, and the cells were washed and analyzed for double-stained cells.
Proliferation assays
A total of 102104 irradiated (100 Gy) CHO-BY55, CHO-CD86, or CHO-mock cells were plated in 96-well round-bottom plates. The T cell clones were used 7 days after stimulation with feeder cells. Purified PBL T cells were used immediately after sorting. A total of 5 x 104 cells per well were cultured in triplicate with: medium alone, soluble CD3 mAb (1.7 µg/ml of CD3 x 3, produced in our laboratory), IL-2 (50 U/ml, Eurocetus, Amsterdam, The Netherlands), or 1 µg/ml PHA-M (Sigma, St. Louis, MO). [3H]TdR incorporation was measured as described previously (14).
| Results and Discussion |
|---|
|
|
|---|
Because of the homology of BY55 with KIRs, we examined whether
BY55 also bound to MHC class I. We performed flow cytometry to detect
conjugate formation between CHO-BY55 and murine L cells expressing
human ß2m and HLA-B7, HLA-E, or HLA-G. CHO-BY55 bound to
HLA-B7, HLA-E, and HLA-G transfectants but not to L cells expressing
ß2m alone (Fig. 1
). The
relatively low level of conjugate formation is attributable to the weak
expression of human MHC class I by the transfectants.
|
We found that CHO-BY55 formed conjugates with human cell lines,
regardless of their MHC class I haplotype (Fig. 2
a shows representative
examples). The specificity of the binding was confirmed by inhibition
with CLI-R2 mAb, which is an IgG1 mAb directed against BY55 but not an
isotype-matched control (L161, anti-CD1c) (data not shown).
Interestingly, experiments designed to block CHO-BY55 binding with the
monomorphic anti-MHC class I mAb W6/32 led to increased conjugate
formation (Fig. 2
b). This effect was specific, as
anti-CD2 mAbs of various isotypes failed to increase conjugate
formation between CHO-BY55 and the CD2+ Cou LS cell line
(data not shown). The MHC class I- Daudi cell line
did not form conjugates with CHO-BY55 in the presence or absence of
W6/32 mAb (Fig. 2
, a and b). These results
suggested that BY55 molecules bound to classical and nonclassical MHC
class I, and that optimal binding required a cross-linking of MHC class
I complexes.
|
To definitively establish that BY55 binds to MHC class I
molecules, we used soluble, recombinant, phycoerythrin-labeled human
HLA-A2 tetramers refolded with different peptides. HLA-A2 tetramers
alone were unable to stain CHO-BY55 as detected by flow cytometry.
However, the cross-linking of tetramers with anti-HLA-A2 mAb led to
a strong staining of CHO-BY55, regardless of the bound peptide (Fig. 3
). The specificity of the binding was
shown by inhibition with CLI-R2 mAb, whereas the IgM anti-BY55 was
ineffective (Fig. 3
a); furthermore, CHO-BY55 was unable to
bind aggregated Ig (FITC-conjugated anti-HLA-A2 mAb cross-linked
with 7S goat anti-mouse Ig). CHO-CD86 or
CHO-mock cells were not stained by the tetramers, even when
cross-linked (Fig. 3
d).
|
Ligation of T cell MHC class I molecules by BY55 delivers a potent costimulatory signal to activated human T cells
As the BY55 molecule is glycosylphosphatidylinositol-linked
(3) and does not have intracytoplasmic immunoreceptor tyrosine-based
inhibitory and activating motifs, this may explain why no role
for BY55 in NK cytotoxicity has been observed (1, 4). We hypothesized
that the BY55/MHC class I interaction might deliver signals to the MHC
class I-bearing target cell. We performed proliferation assays with
human T cell clones of various phenotypes to examine the effect of
triggering their MHC class I complexes with CHO-BY55. Soluble
anti-CD3 mAb alone did not induce proliferation of the clones (Fig. 4
a). When added to soluble
anti-CD3, CHO-BY55 but not CHO-CD86 or CHO-mock triggered a strong
proliferation of T cell clones. This effect was specifically inhibited
by CLI-R2 and not by the IgM anti-BY55 mAb or an isotype control
(Fig. 4
a). CHO-BY55 alone did not induce proliferation.
CHO-CD86 and soluble anti-CD3 did not induce proliferation in
the T cell clones, as they were CD28- or expressed low
levels of CD28. In contrast, T cells from normal PBLs did not
proliferate in response to soluble anti-CD3 and CHO-BY55; however,
as expected, these T cells did respond to the classical combination of
CD3 activation and CD28 costimulation (22) (by soluble anti-CD3 and
CHO-CD86) (Fig. 4
b). Thus, ligation of MHC class I delivers
a costimulatory signal specifically to activated T cells, as quiescent
peripheral blood T lymphocytes did not respond to a combined triggering
of TCR/CD3 and MHC class I complexes. Confirming these observations, we
found that when peripheral blood T cells were driven to proliferate by
anti-CD3 mAb coated onto culture wells, the addition of CHO-BY55
led to a significant amplification of the proliferative response (data
not shown).
|
3 domain of MHC class I molecules
(23), and mAbs specific for the
3 domain can inhibit T cell
activation (24) and induce apoptosis (13). In contrast,
cross-linking MHC class I complexes with CHO cells expressing human CD8
was found to augment the IL-2 secretion of activated CD4+ T
cells (25). Abs against the HLA class I
1 domain preferentially
induced apoptosis in activated T cells (26). MHC class I
ligation by mAbs leads to tyrosine kinase
phosphorylation, which appears to involve the
transduction components of the TCR/CD3 complex (27). The physiological function of MHC class I triggering by BY55 molecules is unknown, but it may have a particular role in intestinal intraepithelial T lymphocytes that have an activated/memory phenotype such as: CD8+, CD45RO+, CD45RA-, CD28-, BY55+, and MHC class I+ (3). What compensates for the loss of CD28, the major costimulatory molecule, has been perplexing. Our findings provide a molecular basis for lymphocyte-lymphocyte interactions between BY55 and MHC class I molecules, which could be responsible for an efficient immune response in effector cells in the absence of CD28 costimulation and may play a role in the maintenance of memory.
In conclusion, activated/memory lymphocytes, such as T cell clones that express low levels of CD28, can be driven to proliferate by a second signal from their MHC class I molecules cross-linked by a natural ligand, BY55. Thus, in addition to Ag presentation, MHC class I molecules are also directly involved in T cell costimulation.
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr Armand Bensussan, Institut National de la Santé et de la Recherche Médicale U448, Faculté de Medecine 8, rue du General Sarrail, 94010 Créteil, France. E-mail address: ![]()
3 Abbreviations used in this paper: KIR, killer inhibitory receptor; CHO, Chinese hamster ovary; ß2m, ß2-microglobulin. ![]()
Received for publication October 15, 1998. Accepted for publication November 23, 1998.
| References |
|---|
|
|
|---|
3 domain of class I MHC. Science 252:1424.
3 domain of human MHC class I molecules. J. Immunol. 153:1054.[Abstract]
-chain, and induces apoptosis. J. Immunol. 158:3189.[Abstract]
This article has been cited by other articles:
![]() |
J. Giustiniani, A. Marie-Cardine, and A. Bensussan A Soluble Form of the MHC Class I-Specific CD160 Receptor Is Released from Human Activated NK Lymphocytes and Inhibits Cell-Mediated Cytotoxicity J. Immunol., February 1, 2007; 178(3): 1293 - 1300. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Fons, S. Chabot, J. E. Cartwright, F. Lenfant, F. L'Faqihi, J. Giustiniani, J.-P. Herault, G. Gueguen, F. Bono, P. Savi, et al. Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells Blood, October 15, 2006; 108(8): 2608 - 2615. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Maeda, C. Carpenito, R. C. Russell, J. Dasanjh, L. L. Veinotte, H. Ohta, T. Yamamura, R. Tan, and F. Takei Murine CD160, Ig-Like Receptor on NK Cells and NKT Cells, Recognizes Classical and Nonclassical MHC Class I and Regulates NK Cell Activation J. Immunol., October 1, 2005; 175(7): 4426 - 4432. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Barakonyi, M. Rabot, A. Marie-Cardine, M. Aguerre-Girr, B. Polgar, V. Schiavon, A. Bensussan, and P. Le Bouteiller Cutting Edge: Engagement of CD160 by its HLA-C Physiological Ligand Triggers a Unique Cytokine Profile Secretion in the Cytotoxic Peripheral Blood NK Cell Subset J. Immunol., November 1, 2004; 173(9): 5349 - 5354. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Le Bouteiller, A. Barakonyi, J. Giustiniani, F. Lenfant, A. Marie-Cardine, M. Aguerre-Girr, M. Rabot, I. Hilgert, F. Mami-Chouaib, J. Tabiasco, et al. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity PNAS, December 24, 2002; 99(26): 16963 - 16968. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nikolova, A. Marie-Cardine, L. Boumsell, and A. Bensussan BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression Int. Immunol., May 1, 2002; 14(5): 445 - 451. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. I. Slukvin, D. P. Lunn, D. I. Watkins, and T. G. Golos Placental expression of the nonclassical MHC class I molecule Mamu-AG at implantation in the rhesus monkey PNAS, August 1, 2000; 97(16): 9104 - 9109. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Poszepczynska, M. Bagot, H. Echchakir, D. Martinvalet, M. Ramez, D. Charue, L. Boumsell, and A. Bensussan Functional characterization of an IL-7-dependent CD4+CD8alpha alpha + Th3-type malignant cell line derived from a patient with a cutaneous T-cell lymphoma Blood, August 1, 2000; 96(3): 1056 - 1063. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |